John Libbey Eurotext

Hématologie

MENU

Anti-BCMA chimeric antigen receptor T-cell therapy in multiple myeloma: despite a strong efficacy, persistence of autologous T cells remains a major challenge Volume 27, supplement 3, Juin 2021

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
Author
Service d’hématologie clinique, hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France
* Tirés à part

Anti-BCMA chimeric antigen receptor T-cell therapy in multiple myeloma is rapidly evolving. As an example, idecabtagene vicleucel should be soon available in routine practice in France. Despite unprecedented high global response rates, durations of response are limited and most of patients eventually relapse. Therefore, viability and persistence of autologous T cells is one of major issues, leading to elaboration of innovative technologies and new constructs. So far, CAR T cells have been mostly used in advanced stages of the disease. However, earlier positioning in relapse setting is mandatory. Other emergent immunotherapies such as bispecific monoclonal antibodies could represent competing therapeutic options.